ANB033 Hits All Endpoints in Celiac Trial, First-Ever Symptom and Histology Win
TRAX has more than doubled off its 52-week low of $14.72.
Summary
First Tracks Biotherapeutics reported positive top-line results from Cohort 1 of its Phase 1b trial of ANB033 in celiac disease. The drug achieved statistically significant improvements versus placebo across all key histologic endpoints—Vh:Cd ratio, IEL density, and VCIEL—and prevented symptom increases during a 14-day gluten challenge. This is the first time a celiac disease drug has shown both symptom prevention and histologic protection in the same study. Safety was clean with no serious adverse events. The company plans to start a late-stage trial in 2027, with Cohort 2 data expected in Q1 2027. This is a major de-risking event for the lead asset in a disease with no approved therapies.
At the time of this announcement, TRAX was trading at $36.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $14.72 to $49.91. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.